Clinical Trial: Dose-finding Study of ASP2151 in Subjects With Herpes Zoster

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter, Randomized, Double-blind, Valacyclovir Hydrochloride-controlled, Parallel-group, Comparative S

Brief Summary: To investigate the efficacy and safety of three different doses of ASP2151, as compared to valacyclovir hydrochloride in subjects with herpes zoster, and to determine the recommended clinical dose.

Detailed Summary:
Sponsor: Astellas Pharma Inc

Current Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir in subjects with Herpes Zoster [ Time Frame: 3 months ]

Original Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir in subjects with Herpes Zoster

Current Secondary Outcome: Improvement of cutaneous symptoms and pain [ Time Frame: 3 months ]

Original Secondary Outcome: Improvement of cutaneous symptoms and pain

Information By: Astellas Pharma Inc

Dates:
Date Received: June 15, 2007
Date Started: August 2007
Date Completion:
Last Updated: December 19, 2011
Last Verified: December 2011